Wednesday, September 9, 2009
PerkinElmer Acquires Sym-Bio Lifescience in Shanghai
PerkinElmer (NYSE:PKI) has acquired Sym-Bio Lifescience, a supplier of diagnostic products to hospitals in China based in Shanghai for RMB 435 million. Sym-Bio is active in the infectious diseases area and has manufacturing in the Shanghai area. PerkinElmer said that it is seeking to expand its prenatal and newborn screening business in China.